• DOI:10.1007/s00277-013-1865-3
• Corpus ID: 12851937

Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)

@article{Kiesewetter2014RituximabPB,
  title={Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)},
  author={Barbara Kiesewetter and Marius E. Mayerhoefer and Julius R Lukas and Christoph Carl Zielinski and Leonhard M{\"u}llauer and Markus Raderer},
  journal={Annals of Hematology},
  year={2014},
  volume={93},
  pages={249-253}
}

• B. Kiesewetter, M. Mayerhoefer, +3 authors M. Raderer
• Published 1 February 2014
• Medicine
• Annals of Hematology

Recently, the combination of rituximab and bendamustine (R-Benda) has been defined as highly active in patients with follicular lymphomas, but little is known about the efficacy of R-Benda in mucosa-associated lymphoid tissue (MALT) lymphoma. In a retrospective analysis, we have defined 14 patients with MALT lymphoma undergoing therapy with R-Benda. Seven patients were female and seven male (aged 44–88 years), and all had relapsed extragastric MALT lymphoma. R-Benda was given at first relapse in ten patients, while four patients had more than two prior forms of therapy. Bendamustine was given at a dose of 90 mg/m2 on days 2 and 3 in ten patients and at 70 mg/m2 in three patients, while all received 375 mg/m2 rituximab on day 1. Ten patients received six courses of therapy, while two patients discontinued therapy after three, and one after four courses for personal reasons, while one patient had progressive disease after four courses. Tolerance of therapy was excellent, and all except one patient responded. Ten patients achieved a complete remission (CR) (71 %), three a partial remission (21 %), while one patient progressed. Toxicities were mild and mainly hematological but did not result in relevant delays or the necessity for dose reductions. After a median follow-up of 23 months (range, 4–42+), 13 patients are alive and one patient has relapsed 23 months after initial CR. Our data suggest high activity and good tolerance of R-Benda in patients with relapsed MALT lymphoma despite intensive pretreatment in some patients. In view of this, prospective studies are warranted.